Aurobindo Pharma Ltd (AUROPHARMA) — shareholding pattern, promoter holding, financials and share price
About Aurobindo Pharma Ltd (AUROPHARMA)
Aurobindo Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as AUROPHARMA and on the BSE under scrip code 524804. Its ISIN is INE406A01037.
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
Aurobindo Pharma Limited is a global pharmaceutical company that develops, manufactures and markets active pharmaceutical ingredients (APIs), generic formulations, injectables and a growing biosimilars portfolio across regulated and growth markets, operating multiple manufacturing sites and R&D centres to serve over 150 countries with a broad ANDA/DMF filing base and expanding biologics capabilities.
Q3FY26 consolidated revenue reached Rs. 8,646 crore, up 8.4% YoY, with EBITDA of Rs. 1,773 crore (20.5% margin) and net profit of Rs. 910 crore; management highlighted stable US base business, strong European growth (+27% YoY) and R&D spend of Rs. 409 crore (4.7% of sales) focused on biosimilars and specialty products development.
Listed peers in Pharmaceuticals: Lupin Ltd, Mankind Pharma Ltd, Dr Reddys Laboratories Ltd, Laurus Labs Ltd, Biocon Ltd, Alkem Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹1,567.6 a share on 10 Jul 2026, Aurobindo Pharma Ltd (AUROPHARMA) was valued at a price-to-earnings ratio of 25.75x against an industry P/E of 36.41x and a price-to-book of 2.76x on a book value of ₹567.51 per share as of Mar 2025. Solomo computes return on equity of 10.73% and return on capital employed of 13.43% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 25.75x
- Industry P/E
- 36.41x
- P/B
- 2.76x
- EPS (TTM)
- ₹60.88
- Book value / share
- ₹567.51
- ROE
- 10.73%
- ROCE
- 13.43%
- ROA
- 7.04%
- Debt / equity
- 0.25x
- Dividend yield
- 0.26%
- EBITDA margin
- 21.79%
- 52-week range
- ₹1,017 – ₹1,636
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Aurobindo Pharma Ltd (AUROPHARMA) reported revenue of ₹33,653 crore, net profit of ₹3,503 crore and earnings per share of ₹60.34. That compares with revenue of ₹31,724 crore and net profit of ₹3,484 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹8,853 crore and net profit ₹921 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 23,455 | 24,855 | 29,002 | 31,724 | 33,653 |
| Net profit (₹ cr) | 2,647 | 1,928 | 3,169 | 3,484 | 3,503 |
| EPS (₹) | 45.2 | 32.9 | 54.15 | 60.02 | 60.34 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 1.79% | -3.95% | -1.06% | 9.39% |
| Profit growth | 0.79% | -1.43% | 6.29% | 9.93% |
| Stock price CAGR | 8% | 10% | 28% | 34% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 51.88% of Aurobindo Pharma Ltd (AUROPHARMA) (up 0.06 pp QoQ), foreign institutional investors (FII) hold 16.38% and domestic institutional investors (DII) hold 25.1%. Promoters have pledged 13.8% of their holding. Market capitalisation was ₹90,196 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: QUANT MUTUAL FUND 4.96%, SBI LARGE & MIDCAP FUND 3.57%, HDFC MUTUAL FUND 3.22%, LIFE INSURANCE CORPORATION OF INDIA 2.94%, NPS TRUST - A/C SBI PENSION FUND SCHEME - NPS TIER 2.74%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 51.88% | 13.8% | 16.38% | 25.1% | 48.12% |
| Mar 2026 | 51.82% | 23.6% | 15.24% | 25.87% | 48.18% |
| Dec 2025 | 51.82% | 17.5% | 13.94% | 27.68% | 48.18% |
| Sep 2025 | 51.82% | 17.5% | 14.21% | 27.6% | 48.18% |
| Jun 2025 | 51.82% | 17.1% | 14.37% | 26.93% | 48.18% |
| Mar 2025 | 51.82% | 16.9% | 15.33% | 26.23% | 48.18% |
| Dec 2024 | 51.82% | 17.8% | 16.29% | 25.2% | 48.18% |
| Sep 2024 | 51.82% | 20.4% | 16.59% | 25.13% | 48.18% |